IRIS - Res&Arch Institutional Research Information System - Research & Archive

MANDALA', Mario
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.955
AS - Asia 5.054
EU - Europa 3.122
SA - Sud America 890
AF - Africa 125
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 13
Totale 15.180
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.815
SG - Singapore 2.780
RU - Federazione Russa 998
IE - Irlanda 719
BR - Brasile 684
IT - Italia 586
CN - Cina 582
HK - Hong Kong 580
VN - Vietnam 435
FR - Francia 255
DE - Germania 165
IN - India 107
KR - Corea 106
GB - Regno Unito 92
BD - Bangladesh 81
AR - Argentina 76
AT - Austria 62
IQ - Iraq 57
TR - Turchia 55
MX - Messico 52
UA - Ucraina 48
CA - Canada 47
FI - Finlandia 44
JP - Giappone 41
CO - Colombia 32
PK - Pakistan 30
SA - Arabia Saudita 29
SE - Svezia 29
ZA - Sudafrica 29
ES - Italia 27
VE - Venezuela 24
PL - Polonia 22
ID - Indonesia 21
NL - Olanda 21
PH - Filippine 21
EU - Europa 20
CL - Cile 19
UZ - Uzbekistan 19
EC - Ecuador 17
ET - Etiopia 14
JO - Giordania 13
KE - Kenya 13
EG - Egitto 12
GR - Grecia 12
MA - Marocco 12
MY - Malesia 12
CH - Svizzera 11
PY - Paraguay 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 10
AU - Australia 10
PS - Palestinian Territory 10
TN - Tunisia 10
DZ - Algeria 9
AZ - Azerbaigian 8
PE - Perù 8
BO - Bolivia 7
IL - Israele 7
LT - Lituania 7
NP - Nepal 7
CR - Costa Rica 6
GE - Georgia 6
PA - Panama 6
CI - Costa d'Avorio 5
HN - Honduras 5
KZ - Kazakistan 5
SN - Senegal 5
LY - Libia 4
OM - Oman 4
RS - Serbia 4
TH - Thailandia 4
AL - Albania 3
BE - Belgio 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
JM - Giamaica 3
LB - Libano 3
NI - Nicaragua 3
SY - Repubblica araba siriana 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
BB - Barbados 2
BH - Bahrain 2
BZ - Belize 2
IR - Iran 2
MM - Myanmar 2
NG - Nigeria 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SV - El Salvador 2
ZW - Zimbabwe 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BQ - ???statistics.table.value.countryCode.BQ??? 1
BW - Botswana 1
CG - Congo 1
CY - Cipro 1
GA - Gabon 1
Totale 15.155
Salva come PNG Salva come JPEG
Città #
Singapore 2.006
Chandler 944
Dublin 718
San Jose 716
Hong Kong 573
Ashburn 332
Santa Clara 291
Boardman 286
Dong Ket 273
Altamura 269
San Mateo 233
Lauterbourg 224
Medford 216
Moscow 213
Princeton 213
Lawrence 207
Andover 186
Los Angeles 154
Wilmington 121
Seoul 106
New York 83
São Paulo 62
Arezzo 57
Redwood City 56
Des Moines 51
Nuremberg 49
Ho Chi Minh City 48
Piscataway 48
Perugia 43
Norwalk 42
San Paolo di Civitate 39
Tokyo 39
Hanoi 35
Shanghai 33
The Dalles 31
Beijing 30
Chicago 30
Frankfurt am Main 29
Baghdad 25
Council Bluffs 25
Helsinki 25
Munich 24
Vienna 24
Redmond 23
Dallas 22
Hefei 22
Rio de Janeiro 22
Montreal 21
Milan 19
San Francisco 19
Brasília 18
Warsaw 18
Belo Horizonte 17
Brooklyn 17
Tianjin 17
Kocaeli 16
London 15
Addis Ababa 14
Guangzhou 14
Saint Petersburg 14
Dhaka 13
Istanbul 13
Jacksonville 13
Jeddah 13
Johannesburg 13
Mexico City 13
Secaucus 13
Columbus 12
Porto Alegre 12
Atlanta 11
Boston 11
Curitiba 11
Rome 11
Amman 10
Chennai 10
Haiphong 10
Nairobi 10
Shijiazhuang 10
Falkenstein 9
Medellín 9
Montevideo 9
Santiago 9
Tashkent 9
Turku 9
Da Nang 8
Denver 8
Florence 8
Guayaquil 8
Houston 8
Lahore 8
Manaus 8
Ribeirão Preto 8
Amsterdam 7
Asunción 7
Bogotá 7
Caxias do Sul 7
Islamabad 7
Jakarta 7
Kuala Lumpur 7
Leighton Buzzard 7
Totale 9.900
Salva come PNG Salva come JPEG
Nome #
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action 131
Chemotherapy-associatedthromboembolic risk in cancer outpatients and effect of nadroparinthromboprophylaxis: results of a retrospective analysis of the PROTECHT study. 109
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial 108
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 triaL 104
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 100
A prospective study on survival in cancer patients with and without venous thromboembolism. 99
Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial 99
Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703 96
A case of sudden brain metastases progression after temporary targeted therapy discontinuation: when to regret a drug holiday 93
Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients 92
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma 92
Primary analysis and four-year follow-up of the phase III NIBIT-M2 trial in melanoma patients with brain metastases 91
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management 90
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma 90
Analysis of the Expression and Single-Nucleotide Variant Frequencies of the Butyrophilin-like 2 Gene in Patients With Uveal Melanoma 90
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism 90
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma 89
Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1 89
Adjuvant therapy in breast cancer and venous thromboembolism 88
Patient-reported outcomes in patients with resected, high-risk melanoma with BRAF(V600E) or BRAF(V600K) mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial 88
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 88
Abrogation of the negative influence of opioids on IL-2 immunotherapy of renal cell cancer by melatonin 85
40. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH 83
Acute endocrine effects of interleukin-12 in cancer patients 82
Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival 82
Acquired Resistance to Clinical Cancer Therapy: A Twist in Physiological Signaling 80
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i 79
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 79
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 79
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial 78
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee 75
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 74
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases 74
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 74
Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song 73
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab 72
Acute dyspnea due to right phrenic palsy during infusional chemotherapy 72
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup 72
Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study 72
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p 71
Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases 71
Treatment of venous thromboembolism in cancer patients: The dark side of the moon 71
Tissue prognostic biomarkers in primary cutaneous melanoma 70
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis 70
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial 70
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer 70
Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility 70
Insights Into Genetic Susceptibility to Melanoma by Gene Panel Testing: Potential Pathogenic Variants in ACD, ATM, BAP1, and POT1 69
Melanoma brain metastases: review of histopathological features and immune-molecular aspects 69
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172) 69
The density and spatial tissue distribution of CD8+ and CD163+immune cells predict response and outcome in melanoma patients receiving MAPK inhibitors 69
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study 69
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma 69
Wnt/β-catenin signaling in melanoma: Preclinical rationale and novel therapeutic insights 69
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 68
BRAFV600 variant allele frequency predicts outcome in metastatic melanoma patients treated with BRAF and MEK inhibitors 68
Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma 68
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 68
AKT-ions with a TWIST between EMT and MET 68
Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis 68
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. 67
Prevalence and Clinical Impact of SARS-CoV-2 Silent Carriers Among Actively Treated Patients with Cancer During the COVID-19 Pandemic 67
An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system 67
Association of socioeconomic status with Breslow thickness and disease-free and overall survival in stage I-II primary cutaneous melanoma 66
Targeting BRAF in melanoma: Biological and clinical challenges 66
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action 66
Dehydroepiandrosterone sulfate (DHEAS) secretion in early and advanced solid neoplasms: selective deficiency in metastatic disease 66
Efficacy of bromocriptine in the treatment of metastatic breast cancer- and prostate cancer-related hyperprolactinemia 66
Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time? 66
Is there a right-sided shift for colorectal cancer in women compared with men? 65
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 65
The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma 65
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients 65
Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study 64
European e-Delphi process to define expert consensus on electrochemotherapy treatment indications, procedural aspects, and quality indicators in melanoma 64
Venous thromboembolism and cancer: new issues for an old topic 64
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status 64
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 64
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation-positive melanoma receiving adjuvant vemurafenib 64
Self-monitoring versus standard monitoring of oral anticoagulation 63
A case of severe pharyngeal-cervical-brachial syndrome induced by nivolumab and responding to infliximab therapy 63
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: A multicenter international retrospective study 62
Buprenorphine-induced acute respiratory depression during ifosfamide-based chemotherapy 62
Adjuvant therapy of colon cancer. State of the art and future perspectives 62
mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition 62
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study 62
SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study 62
Correlation of BRAF mutational status with clinical characteristics and survival outcomes of patients with ameloblastoma: the experience of 11 Italian centres 62
DOACs in patients with brain cancers: promising but still a long way to go 61
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma 61
Targeted therapy for advanced cutaneous melanoma 61
Multimodal treatment of advanced mucosal melanoma in the era of modern immunotherapy 61
GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis 61
BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome 61
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer 61
Intratumoral cellular heterogeneity: Implications for drug resistance in patients with non-small cell lung cancer 61
Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma 61
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis 60
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial 60
Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications 60
Totale 7.385
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.627
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 80.627
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021292 0 0 0 0 0 0 0 0 0 0 0 292
2021/20221.188 8 227 9 2 18 7 31 444 9 44 165 224
2022/20233.040 217 524 28 237 274 391 0 164 1.062 9 95 39
2023/2024981 90 154 53 28 18 5 143 9 96 122 99 164
2024/20253.186 34 296 24 82 406 143 92 136 1.173 258 285 257
2025/20266.487 644 444 267 492 841 527 1.223 529 586 652 202 80
Totale 15.573